No Photo Available

Last Update

2016-10-08T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Peter Mueller?

Dr. Peter R. Mueller

President of Research and Development and CSO

Pronutria Biosciences Inc

Direct Phone: (617) ***-**** ext. ***       

Email: p***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Pronutria Biosciences Inc

840 Memorial Drive Third Floor Entrance On Blackstone Street

Cambridge, Massachusetts 02139

United States

Company Description

Pronutria Biosciences is pioneering new nutritional and therapeutic modalities: amino acid biologics. Amino acids (AA) are known as the "building blocks of life," and are fundamental regulators of health. The entire body, ranging from microscopic cells to ... more

Find other employees at this company (52)

Background Information

Employment History

Chief Scientific Officer and Executive Vice President of Global Research and Development

Vertex Pharmaceuticals Incorporated

Senior Vice President, Research and Development

Boehringer Ingelheim Corporation

President

R&D Companies

President

Epicenter Consulting LLC

Chief Operating Officer

Amarillo Biosciences , Inc.

Vice President, Global Marketing and Medical Information and Technology

Aventis SA

Director of Global Commercial Development

Marion Merrell Dow

Affiliations

Advisory Board Member
USA India Chamber of commerce

Member
Gesellschaft Deutscher Chemiker

Board Member
Inhibikase Therapeutics Inc

Advisory Board Member
Phacilitate Limited

Scientific Advisory Board Member
Keystone Symposia

Advisory Board Member
Biosensor Forum

Delegate
GDS International Ltd

Faculty Member
Albert Einstein University of Ulm , Germany

Member
American Association for the Advancement of Science

Member
Royal Society of Chemistry

Member
The RNA Society

Member of Council On Economic Competitiveness and Technology for the State of Connecticut
Govenor Roland

Education

MBA

Babson

Ph.D.

Pharmacology

University of Mainz

Ph.D. degree

pharmaceuticals

University of Mainz , Germany

PhD

Chemistry

Albert Einstein University of Ulm , Germany

undergraduate degree

Albert Einstein University of Ulm , Germany

Web References (176 Total References)


USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships

usaindiachamber.org [cached]

Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences

...
Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences
...
Dr. Peter Mueller President R&D and CSO
...
Peter Mueller, PhD; President R&D and Chief Scientific Officer, Pronutria BioSciences


Peter Mueller, Ph.D., President of R&D and Chief Scientific Officer , Pronutria BioSciences LLC

usaindiachamber.org [cached]

Peter Mueller, Ph.D. President of R&D and Chief Scientific Officer Pronutria BioSciences LLC

In November 2014, Dr. Mueller joined Pronutria Biosciences LLC as the President of Research and Development & Chief Scientific Officer. Prior to his time at Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals, starting there in 2003. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible to build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, Clinical and Non-Clinical Development, Regulatory and Medical Affairs as well as Patient Safety. Key areas of Vertex' R&D have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) or its European counterpart the Galenus Preis (Kalydeco). The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration. In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD, Cancer, TB). Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


Peter Mueller, Ph.D., President of R&D and Chief Scientific Officer , Pronutria BioSciences LLC

www.usaindiachamber.org [cached]

Peter Mueller, Ph.D. President of R&D and Chief Scientific Officer Pronutria BioSciences LLC

In November 2014, Dr. Mueller joined Pronutria Biosciences LLC as the President of Research and Development & Chief Scientific Officer. Prior to his time at Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals, starting there in 2003. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible to build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, Clinical and Non-Clinical Development, Regulatory and Medical Affairs as well as Patient Safety. Key areas of Vertex' R&D have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases. His leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia. Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) or its European counterpart the Galenus Preis (Kalydeco). The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration. In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD, Cancer, TB). Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships

www.usaindiachamber.org [cached]

Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences

...
Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences
...
Dr. Peter Mueller President R&D and CSO
...
Peter Mueller, PhD; President R&D and Chief Scientific Officer, Pronutria BioSciences


Peter Mueller, PhD President ...

www.essentientinc.com [cached]

Peter Mueller, PhD President of R&D and Chief Scientific Officer

Similar Profiles

Other People with this Name

Other people with the name Mueller

Cindy Mueller
American Council of Learned Societies

Todd Mueller
Tri-Film Productions LTD

Jane Mueller
Accenture LTD

Lori Mueller
BCS Incorporated

Alan Mueller
Marsh Darcy Partners , Inc.

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory